Abstract:Objective:To investigate the effects of lithium combined with quetiapine or modified electroconvulsive therapy(MECT) on serum brain-derived neurotrophic factor(BDNF) in patients with depressive episode of bipolar disorder(BD) and its relationship with therapeutic effect.Method:Based on BD criteria of diagnostic and statistical manual of mental disorders 4th edition(DSM-IV),80 patients with depressive episode of BD(case group) and 42 healthy controls(control group) were enrolled.Patients were randomly assigned into quetiapine group who were treated with lithium and quetiapine and MECT group who received lithium and MECT.The serum BDNF level and Hamilton rating scale for depression(HAMD) were assayed before and after 4-week treatment.Results:After 4-week treatment,36 patients in quetiapine group and 31 ones in MECT group completed the study;There was a significant difference in the BDNF level before treatment between case and control groups(P<0.01);The levels of BDNF in both drug and MECT groups increased after 4-week treatment(t=-6.04,-5.80;all P<0.01).The HAMD score after treatment significantly decreased than that before treatment(t=16.18,17.51;all P<0.01);Pearson correlation analysis showed that the change of BDNF level was negatively correlated with the change of HAMD score before and after treatment in case group(r=-0.30,P=0.013).Conclusion:Patients with depressive episode of BD have significantly decreased serum level of BDNF than healthy controls.Lithium combined with quetiapine or MECT could improve symptoms and increase BDNF level.BDNF may be the potential biomarker for the treatment of BD with depressive episode.

Effects of lithium combined with quetiapine or modified electroconvulsive therapy on brain derived neurotrophic factor in patients with depressive episode of bipolar disorder